Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis
Background: This article is based on our previous research, which was presented at the 2023 ASCO Annual Meeting I and published in Journal of Clinical Oncology as Conference Abstract (JCO. 2023;41:e16148. doi: 10.1200/JCO.2023.41.16_suppl.e16148). Both anti-programmed death 1/ligand-1 (PD-1/L1) anti...
Saved in:
| Main Authors: | , , |
|---|---|
| 格式: | 图书 |
| 出版: |
Open Exploration Publishing Inc.,
2024-06-01T00:00:00Z.
|
| 主题: | |
| 在线阅读: | Connect to this object online. |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
| 索引号: |
A1234.567 |
|---|---|
| 复印件 1 | 可用 |